# Phase 1/2 Leukemia, Myeloid, Acute trials: 90 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 90 trials in phase 1/2 for Leukemia, Myeloid, Acute that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Leukemia, Myeloid, Acute trials: 90 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/leukemia-myeloid-acute

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 90
- Recruiting or not yet: 90
- Read on: November 19, 2026

## Trials

The 25 newest of 90, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939971 | A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML | TuHURA Biosciences, Inc. | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939971) |
| November 9, 2026 | NCT07926607 | Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | Second Affiliated Hospital of Nanchang University | Phase 1/2 | Not yet recruiting | Acute Myeloblastic Leukemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926607) |
| October 16, 2026 | NCT07877610 | CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Phase 1/2 | Recruiting | AML (Acute Myeloid Leukemia), BPDCN | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877610) |
| October 14, 2026 | NCT07873827 | KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies | Stemline Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | Hematological Malignancy | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873827) |
| August 18, 2026 | NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | BeOne Medicines | Phase 1/2 | Not yet recruiting | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770698) |
| August 12, 2026 | NCT07761533 | PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS | Chaser Therapeutics, Inc. | Phase 1/2 | Recruiting | Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome) | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761533) |
| August 11, 2026 | NCT07757672 | Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML. | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Not yet recruiting | AML (Acute Myelogenous Leukemia, HSCT | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757672) |
| August 6, 2026 | NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | Vitruviae | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor... | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749976) |
| July 24, 2026 | NCT07726576 | Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia | University Hospital, Bordeaux | Phase 1/2 | Not yet recruiting | Leukemia, Myeloid, Acute | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726576) |
| July 23, 2026 | NCT07722312 | S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory... | Servier | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722312) |
| July 22, 2026 | NCT07719348 | A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies | Servier | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719348) |
| June 23, 2026 | NCT07663864 | Luspatercept for CIA in AML | Guangdong Second Provincial General Hospital | Phase 1/2 | Recruiting | Chemotherapy-inducing Anemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663864) |
| May 18, 2026 | NCT07591649 | Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT | Masonic Cancer Center, University of Minnesota | Phase 1/2 | Recruiting | Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591649) |
| May 13, 2026 | NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies | Shenzhen University General Hospital | Phase 1/2 | Recruiting | B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584889) |
| April 16, 2026 | NCT07532824 | Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS | Institute of Hematology and Blood Transfusion, Czech Republic | Phase 1/2 | Recruiting | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Proton Therapy, MDS and AML Prior to Allogeneic SCT... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532824) |
| April 13, 2026 | NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | Beijing Biotech | Phase 1/2 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523555) |
| March 20, 2026 | NCT07486726 | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | Shanghai Jiao Tong University School of Medicine | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML) | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486726) |
| March 13, 2026 | NCT07471789 | Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients... | Gyala Therapeutics | Phase 1/2 | Recruiting | Acute Myeloblastic Leukaemia, Leukemia, T-Cell | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07471789) |
| March 5, 2026 | NCT07451912 | Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML | The First Affiliated Hospital of Soochow University | Phase 1/2 | Recruiting | Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07451912) |
| February 13, 2026 | NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410494) |
| January 28, 2026 | NCT07372885 | GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia | University of Manchester | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic, Cord Blood Stem Cell... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07372885) |
| January 27, 2026 | NCT07370064 | Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia | Xuzhou Medical University | Phase 1/2 | Not yet recruiting | AML (Acute Myeloid Leukemia) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07370064) |
| January 21, 2026 | NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | Memorial Sloan Kettering Cancer Center | Phase 1/2 | Recruiting | Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia... | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356154) |
| September 4, 2025 | NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar... | AstraZeneca | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07155226) |
| September 3, 2025 | NCT07153068 | SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Recruiting | T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07153068) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 11 |
| Fred Hutchinson Cancer Center | 3 |
| Masonic Cancer Center, University of Minnesota | 2 |
| Servier | 2 |
| Essen Biotech | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Nationwide Children's Hospital | 2 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 2 |
| Shenzhen Geno-Immune Medical Institute | 2 |
| Xuzhou Medical University | 2 |
| Guangdong Second Provincial General Hospital | 1 |
| TuHURA Biosciences, Inc. | 1 |
| Ellipses Pharma | 1 |
| [AB Science](https://specstream.ai/data/clinical-trials/company/ab-science) | 1 |
| [Stemline Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/stemline-therapeutics-inc) | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| University Hospital, Basel, Switzerland | 1 |
| Chordia Therapeutics, Inc. | 1 |
| Haukeland University Hospital | 1 |
| Zhujiang Hospital | 1 |
| Cullinan Therapeutics Inc. | 1 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 1 |
| Gyala Therapeutics | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 42 |
| China | 26 |
| France | 11 |
| Spain | 9 |
| United Kingdom | 7 |
| Australia | 6 |
| Germany | 6 |
| Italy | 6 |
| Netherlands | 4 |
| Canada | 4 |
| South Korea | 4 |
| New Zealand | 3 |
| Sweden | 3 |
| Switzerland | 2 |
| Japan | 2 |
| Belgium | 2 |
| Puerto Rico | 2 |
| Greece | 1 |
| Norway | 1 |
| Denmark | 1 |
| Singapore | 1 |
| Taiwan | 1 |
| Brazil | 1 |
| Czechia | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [General dentistry practices in the United States](https://specstream.ai/data/businesses/general-dentistry-practices/united-states)
- [Polynesian restaurants in the United States](https://specstream.ai/data/businesses/polynesian-restaurants/united-states)
- [Architectural design firms in the United States](https://specstream.ai/data/businesses/architectural-design-firms/united-states)
- [European restaurants in the United States](https://specstream.ai/data/businesses/european-restaurants/united-states)
- [Orthotics providers in the United States](https://specstream.ai/data/businesses/orthotics-providers/united-states)
- [Welding companies in the United States](https://specstream.ai/data/businesses/welding-companies/united-states)
